drugset / Trial / NCT07247383
Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma
Phase 2
Active not recruiting
39 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II, prospective clinical study to evaluate the efficacy and safety of Orelabrutinib combined with Low-Dose Radiotherapy or Rituximab in the treatment of Ocular Adnexal MALT Lymphoma
Timeline
- Start
- 2025-09-19
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orelabrutinib | Small molecule | 150 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |